Purple Biotech (PPBT) FCF Payout Ratio Growth (1y) (2018 - 2026)
Purple Biotech (PPBT) FCF Payout Ratio Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 68.88% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -31.89% |
| 10 | Purple Biotech | 130.35 | 130.35 | - | -80.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.87% |
| Sep 30, 2025 | -1,480.83% |
| Jun 30, 2025 | -22.92% |
| Mar 31, 2025 | -48.52% |
| Sep 30, 2024 | -42.55% |
| Jun 30, 2024 | -2.89% |
| Mar 31, 2024 | 45.58% |
| Dec 31, 2023 | 17.55% |
| Sep 30, 2023 | -29.27% |
| Jun 30, 2023 | -65.26% |
| Mar 31, 2023 | 20.45% |
| Dec 31, 2022 | -1,265.57% |
| Sep 30, 2022 | 65.35% |
| Jun 30, 2022 | 3,855.77% |
| Mar 31, 2022 | -46.73% |
| Dec 31, 2021 | 84.93% |
| Dec 31, 2020 | -29.14% |
| Dec 31, 2019 | -28.04% |
| Dec 31, 2018 | -2.98% |